Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases

Not Applicable

Active, not recruiting

• Conditions: Metastatic Breast Cancer; Metastatic Prostate Cancer; Metastatic Lung Cancer; Bone Metastases
• Interventions: Radiation: SBRT

• Registration Number: NCT03143322
• Lead Sponsor: UNICANCER

Brief Summary

Bone metastases occur frequently during the evolution of solid tumors, either isolated or associated with visceral metastases. The incidence varies between 20 and 85% depending on the primary cancer. Breast, prostate, and lung cancers are responsible for 70% of bone metastases. Cancer with bone metastases compared to other metastatic sites is considered as associated with a better prognosis, particularly for breast and prostate cancer. Bone metastases may be present at diagnosis (synchronous metastasis) or appear at a later time (metachronous metastasis).

The concept of "oligometastases" was proposed in patients with about 3 up to 5 metastases (without restriction on the primary site) and associated with an intermediate prognosis. It was hypothesized that local treatment with curative intent, aiming at the few metastatic sites, would yield long-term survival probabilities, along with systemic therapies.

Long-term survivors have been reported after curative-intent treatment of metastasis in sarcoma and colorectal cancers with liver or lung metastasis. We chose to focus on bone metastasis because of their high incidence, their impact on the patient's quality of life and autonomy, and their accessibility to potentially curative radiotherapy.

The systemic treatment of metastatic cancer includes hormonal therapy (breast and prostate cancer), biologically-targeted drugs and chemotherapy (all cancers).

Stereotactic radiotherapy is a highly accurate technique was initially developed for performing the radiosurgery of brain tumors in patients for whom it was deemed be too difficult to proceed to classical excision surgery. In this process, a high total dose of radiation is delivered in a single fraction to a well-defined intra-cranial target. The concept of radiotherapy in stereotactic conditions was extended to one or several fractions delivered to small volumes primary tumors/ metastases in extra-cranial sites (Stereotactic Body RadioTherapy \[SBRT\]). At present, high control rates have been achieved for lung metastases. Similarly, very high local control rates have been reported in bone metastases after stereotactic radiotherapy.

In this protocol, our purpose is to demonstrate, via a randomized phase III trial, that high doses of radiotherapy, delivered in stereotactic conditions to the bone metastases (between 1 and 5 metastases) in solid tumor patients is able to improve the survival without progression.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2017-04-28
• Study First Submitted QC: 2017-05-03
• Study First Posted: 2017-05-08
• Study Start: 2018-07-24
• Status Verified: 2024-11
• Last Update Submitted: 2024-11-25
• Last Update Posted: 2024-11-26
• Primary Completion: 2025-07-22
• Study Completion: 2027-07-22

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 168

Inclusion Criteria

1. Patients older than 18 years and younger than 75 years
2. Good general condition: WHO performance status ≤ 2
3. Patients with histological proof of breast, non-small cell lung, or prostate cancer Note: Histological proof can be done on the primitive tumour and/or adenopathy and/or metastatic site.
4. Absence of co-morbidity contra-indicating radio-chemotherapy or surgery
5. Primary tumor accessible to curative-intent treatment (surgery, chemoradiation...) for patients with synchronous metastases
6. Patients with between 1 and 5 synchronous or metachronous bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if necessary) within 6 weeks before randomization)
7. Bones metastases treatable by SBRT
8. Primary cancer considered to be controlled or accessible to curative-intent treatment (surgery, chemoradiation...) in case of locoregional recurrence for metachronous bone oligo-metastatic disease
9. Women of childbearing potential and male patients must agree to use adequate contraception for the duration of study participation and up to 3 months following completion of therapy
10. Patients who have received the information sheet, dated and signed the informed consent form
11. Affiliated to the social security system

Exclusion Criteria

1. Visceral metastases as defined by FDG-PET (F-Choline-PET or PSMA PET-CT for prostate cancer) and cerebral CT or MRI performed.
2. Previous systemic therapy for metastasis for patients with metachronous metastasis. Prostate and breast cancer patients remain eligible if hormonal treatment was initiated 6 months before enrollment
3. All bone metastasis requiring surgical treatment (spinal cord compression, fracture...)
4. More than 5 bone metastases as defined by NaF-PET or conventional SPECT-CT scan and spinal MRI (if spinal bone metastases on NaF-PET)
5. Previous cancer within the 5 years before inclusion (except basal cell carcinoma of the skin, in situ carcinoma of the uterine cervix)
6. Previous radiotherapy on bone metastasis (e.g: antalgic radiotherapy)
7. Patient enrolled in another therapeutic trial
8. Pregnant women or breast feeding mothers,
9. Hypersensitivity to the active substance (FDG and NaF or F-Choline or PSMA for prostate cancer) or to any of the excipients
10. Contraindication to MRI (in case of spinal metastases)
11. Patients deprived of liberty or placed under the authority of a tutor. Patients with any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial. Patients unable to understand the purpose of the study (language, etc.).

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Systemic treatment + SBRT	SBRT	Systemic treatment and SBRT to the bone metastases. Two SBRT schemes are allowed: 9 Gy x 3 fractions or 7 Gy x 5 fractions for axial and appendicular bones metastases. The choice is at the discretion of the investigator.

Primary Outcome Measures

Name	Time	Method
Progression Free Survival	1 year	To evaluate the impact of SBRT on Progression-Free Survival (PFS) at 1 year according to RECIST 1.1 and PERCIST 1.0 Criteria

Secondary Outcome Measures

Name	Time	Method
Local control at 1, 2 and 3 years	1, 2 and 3 years after treatment	Local control will be evaluated at 1, 2 and 3 years according to RECIST Criteria 1.1 and PERCIST
Cancer-specific survival	1, 2 and 3 years after treatment	The length of time from the start of treatment for the disease until the death identified as being due to the specified cancer.
Overall survival	1, 2 and 3 years after treatment	The length of time from the start of treatment for the disease until patients are still alive.
PFS at 2 and 3 years	2 years and 3 years after treatment	Progression-Free Survival (PFS) at 2 and 3 years will be evaluated according to RECIST 1.1 and PERCIST
SBRT toxicities	1, 2 and 3 years after treatment	according CTCAE 4.0 scale
Patient's Quality of life	at baseline, 6 weeks after randomization, and 3 months, 6 months and 1, 2 and 3 years after treatment	self-administered questionnaire
Pain score	at baseline, once a week during 2 weeks and 6 weeks after randomization, and at 3 months, 6 months and 1, 2 and 3 years after treatment	according to Numeric Scale related to pain medication
Bone progression free survival at 1, 2 and 3 years	1, 2 and 3 years after treatment	Distant bone progression at 2 and 3 years will be evaluated according to RECIST Criteria 1.1 and at 1 year according to RECIST Criteria 1.1 and PERCIST
Cost utility	6 weeks after randomization	QALYs (Quality-Adjusted Life Years) and ICERs (Incremental Cost-Effectiveness Ratios) calculation based on EQ-5D-3L questionnaire.

Trial Locations

Locations (28)

ICO - Site Paul Papin; 🇫🇷 Angers, France

Centre Catalan D'Oncologie; 🇫🇷 Perpignan, France

Centre Marie Curie; 🇫🇷 Arras, France

Hôpital Privé Les Bonnettes; 🇫🇷 Arras, France

Institut Sainte Catherine; 🇫🇷 Avignon, France

Centre Pierre Curie; 🇫🇷 Beuvry, France

Clinique Ambroise Pare; 🇫🇷 Beuvry, France

Clinique Tivoli Ducos; 🇫🇷 Bordeaux, France

Institut Bergonié; 🇫🇷 Bordeaux, France

Pôle Leonard de Vinci; 🇫🇷 Chambray-lès-Tours, France

Hôpital Métropole Savoie; 🇫🇷 Chambéry, France

Centre Amethyst CROM; 🇫🇷 Creil, France

Hôpital Henri Mondor; 🇫🇷 Créteil, France

Centre Léonard de Vinci; 🇫🇷 Dechy, France

Institut de Cancérologie de Bourgogne; 🇫🇷 Dijon, France

Chu Grenoble; 🇫🇷 Grenoble, France

Centre Oscar Lambret; 🇫🇷 Lille, France

Hôpital Privé Le Bois; 🇫🇷 Lille, France

Centre Léon Bérard; 🇫🇷 Lyon, France

Institut Paoli Calmettes; 🇫🇷 Marseille, France

Centre de Cancérologie du Grand Montpellier; 🇫🇷 Montpellier, France

Institut de Cancérologie de Lorraine; 🇫🇷 Nancy, France

Institut de Cancérologie de l'Ouest; 🇫🇷 Nantes, France

Institut Jean Godinot; 🇫🇷 Reims, France

Centre Henri Becquerel; 🇫🇷 Rouen, France

Centre d'oncologie et radiothérapie Saint-Jean; 🇫🇷 Saint-doulchard, France

GCS RISSA - Institut de cancérologie Paris Nord; 🇫🇷 Sarcelles, France

Clinique des dentellières; 🇫🇷 Valenciennes, France